Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience

Elie El Rassy, Marwan Ghosn, Fadi Farhat, Ziad Bakouny, Tarek Assi, Georges Chahine, Fadi Nasr, Fady Ghassan Haddad, Fadi El Karak, Joseph Kattan

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

3 Citations (Scopus)

Résumé

Background: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. Methods: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. Results: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common. Conclusion: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.

langue originaleAnglais
Pages (de - à)121-125
Nombre de pages5
journalBreast Care
Volume13
Numéro de publication2
Les DOIs
étatPublié - 1 avr. 2018
Modification externeOui

Contient cette citation